Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

258
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
258
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

266
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
266
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

663
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
663
Electron Transport Chain: Complex I and II01:46

Electron Transport Chain: Complex I and II

14.9K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
14.9K
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists01:30

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

199
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
199
Electroconvulsive Therapy01:30

Electroconvulsive Therapy

138
Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early...
138

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Knockdown of Ddx3x in mPFC induces autistic-like phenotype in mice via altered synaptic plasticity.

Translational psychiatry·2026
Same author

An Integrative Strategy Enhancing Nanobody Thermostability via CDR Grafting, In Silico Mutagenesis Screening, and Multiplex Evaluation.

ACS synthetic biology·2025
Same author

Vanadium Carbide Quantum Dots Exert Efficient Anti-Inflammatory Effects in Lipopolysaccharide-Induced BV2 Microglia and Mice.

Small science·2025
Same author

Selenoprotein W modulates tau homeostasis in an Alzheimer's disease mouse model.

Communications biology·2024
Same author

The Deficits of Insulin Signal in Alzheimer's Disease and the Mechanisms of Vanadium Compounds in Curing AD.

Current issues in molecular biology·2023
Same author

Fluorescent Sensing Platforms for Detecting and Imaging the Biomarkers of Alzheimer's Disease.

Biosensors·2023

Related Experiment Video

Updated: Sep 3, 2025

Quantitative Analysis of Mitochondria-Associated Endoplasmic Reticulum Membrane (MAM) Stabilization in a Neural Model of Alzheimer's Disease (AD)
06:41

Quantitative Analysis of Mitochondria-Associated Endoplasmic Reticulum Membrane (MAM) Stabilization in a Neural Model of Alzheimer's Disease (AD)

Published on: January 10, 2025

655

Ebselen Interferes with Alzheimer's Disease by Regulating Mitochondrial Function.

Xuexia Li1,2,3,4, Qingqing Shi5, Hao Xu1

  • 1Guangdong Provincial Key Laboratory for Plant Epigenetics, College of Life Sciences and Oceanography, Shenzhen University, Shenzhen 518055, China.

Antioxidants (Basel, Switzerland)
|July 27, 2022
PubMed
Summary

Ebselen, a compound previously found toxic at high doses, effectively improved cognition and reduced Alzheimer

Keywords:
Alzheimer’s diseaseAβEbselenmitochondriasynapse

More Related Videos

Interactions with and Membrane Permeabilization of Brain Mitochondria by Amyloid Fibrils
15:04

Interactions with and Membrane Permeabilization of Brain Mitochondria by Amyloid Fibrils

Published on: September 28, 2019

6.0K
Quantitative Measurement of γ-Secretase-mediated Amyloid Precursor Protein and Notch Cleavage in Cell-based Luciferase Reporter Assay Platforms
06:40

Quantitative Measurement of γ-Secretase-mediated Amyloid Precursor Protein and Notch Cleavage in Cell-based Luciferase Reporter Assay Platforms

Published on: January 25, 2018

6.9K

Related Experiment Videos

Last Updated: Sep 3, 2025

Quantitative Analysis of Mitochondria-Associated Endoplasmic Reticulum Membrane (MAM) Stabilization in a Neural Model of Alzheimer's Disease (AD)
06:41

Quantitative Analysis of Mitochondria-Associated Endoplasmic Reticulum Membrane (MAM) Stabilization in a Neural Model of Alzheimer's Disease (AD)

Published on: January 10, 2025

655
Interactions with and Membrane Permeabilization of Brain Mitochondria by Amyloid Fibrils
15:04

Interactions with and Membrane Permeabilization of Brain Mitochondria by Amyloid Fibrils

Published on: September 28, 2019

6.0K
Quantitative Measurement of γ-Secretase-mediated Amyloid Precursor Protein and Notch Cleavage in Cell-based Luciferase Reporter Assay Platforms
06:40

Quantitative Measurement of γ-Secretase-mediated Amyloid Precursor Protein and Notch Cleavage in Cell-based Luciferase Reporter Assay Platforms

Published on: January 25, 2018

6.9K

Area of Science:

  • Neuroscience
  • Pharmacology
  • Biochemistry

Background:

  • Alzheimer's disease (AD) poses a significant global health challenge with no effective treatments.
  • Previous research indicated Ebselen's cognitive benefits in AD models but also noted toxicity at high concentrations (10.94 μM).
  • This study investigates Ebselen's therapeutic potential and mechanism at a lower, non-toxic concentration.

Purpose of the Study:

  • To evaluate the therapeutic effects of a lower concentration of Ebselen on Alzheimer's disease.
  • To elucidate the molecular mechanisms underlying Ebselen's action in AD mouse models.
  • To assess Ebselen's impact on cognitive function, neuropathology, and mitochondrial health.

Main Methods:

  • Behavioral tests were conducted to assess cognitive abilities in AD mice.
  • Western blot, thioflavin T staining, and transmission electron microscopy were used for pathological evaluation.
  • Mitochondrial function was assessed using assays for membrane potential and respiration.

Main Results:

  • Ebselen treatment significantly enhanced cognitive function in AD mice.
  • The compound reduced amyloid-beta (Aβ) oligomers and repaired synaptic damage.
  • Ebselen restored mitochondrial morphology and function by improving energy metabolism, biogenesis, and fusion/fission balance.

Conclusions:

  • Ebselen demonstrates therapeutic potential for Alzheimer's disease at lower concentrations.
  • The drug's efficacy is linked to its protective effects on mitochondria.
  • Ebselen may represent a promising therapeutic agent for AD by targeting mitochondrial dysfunction.